It i s generally recognized that high levels of low density lipoprotein are associated with the development of atherosclerosis A considerable body of evidence has accumulated to indicate that a critical step in atherogenesis, i s oxidation of LDL, and that circumstances that promote oxidation of LDL may constitute a major risk-factor for atherosclerosis (1) A major catalyst of lipoprotein oxidation in vivo i s the enzyme 15-ltpoxygenase This enzyme can oxidize polyunsaturated fatty acids present in intact lipids and lipoproteins Steinberg has estimated that up to 75% of the oxidative damage to LDL by macrophages i s caused by 15-lipoxygenase Atherosclerotic lesions in rabbit aorta contain increased 15-lipoxygenase activity (2) and oxidized LDL epitopes colocalize with immunoreactive 154ipoxygenase protein in the lesions (1) Hypercholesterolemia is associated with increased 15-lipoxygenase in a number of rabbit tissues -particularly lungwhere elevations of several hundred fold were observed in some animals (3) Systemic induction of the 154ipoxygenase was duplicated by administration of the cytolytic agent phenylhydrazine, and was accompanied by systemic lipoprotein oxidation detected by accumulation of the characteristic oxidation products 15-HETE and 13-HODE in the serum lipids
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The phenomenon of a hyperresponsive 15-lipoxygenase phenotype was encountered during analysis of vascular tissues in hypercholesterolemic rabbits Of a total of 32 rabbits, 7 animals (21 %) were hyperoxidizers with elevations of 15-lipoxygenase in the range of 150-250 units/g, compared to a normal level of 0 5-1 units/g 10 Rabbits were in the medium range (5-25 units/@ and 15 were in the low range (1-5 unitdg) In studies with human blood donors, similar elevations in 1 5-lipoxygenase activity in polymorphonuclear leukocytes, have been observed in response to cytolytic concentrations of drugs such as ibuprofen (4, 5) The 15-lipoxygenase responses of PMN's from a group of 20 subjects were therefore analyzed for evidence of a hyperoxidizer phenotype (Table 1) Bawl levels of the enzyme were low in all subjects, averaging 0 64 i-12 unitdl0' (ells A hyperoxidizer profile was obwrved in almost half (45%) of the tested subjects, with 15-Iipoxygendse elevations in the 11-70 fold range The remaining individual5 diyddyed responses in the low to medium (2-10 fold) rdnge The hyperoxidizer profile was reproducible when subjects wcw te5ted at intervals up to 3 months, suggesting that it was probably an inherent characteristic of the individual rather than a temporary phenomenon due to some environmental or other c,xternal c irc umstance
The results were further analyzed to determine if the basal levels of 154ipoxygenase in PMN's are predictive of the hyperoxidizer profile. The basal and activated levels of the enzyme for 4 individuals who were hyperoxidizers are compared in Figure 1 In general, the basal level of the enzyme was not predictive of the hyperoxidizer profile, since individuals such as subjects #6 and #7 with basal levels in the low range, displayed 10-20 fold activation, whereas subject # 3 with an above average basal level gave less than a 30% elevation following drug treatment. Of interest also is the retest of subject # 7 after 4 week interval, indicating the stability of the hyperoxidizer phenotype.
It has been shown that systemic activation of the 15-Iipoxygenase in rabbits is associated with increased lipoprotein oxidation (3). The results reported here in humans raise the question whether a hyperoxidizer phenotype is associated with an increased risk of lipoprotein oxidation and atherosclerosis, and whether antioxidant vitamin therapy is protective. Experiments to determine if the hyperoxidizer phenotype is associated with a family history of atherosclerosis are now being planned.
